Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA

Sofosbuvir Plus Daclatasvir With or Without Ribavirin for Chronic Hepatitis C Infection: Impact of Drug Concentration on Viral Load Decay

Sofosbuvir plus daclatasvir with or without ribavirin is one of the currently recommended treatment option for chronic hepatitis C. The objectives were to identify factors associated with sofosbuvir/daclatasvir plasma concentrations variations and to evaluate their impact on viral kinetics.

Inclusion Criteria:

• Patients with hepatitis C virus infection treated with sofosbuvir/daclatasvir
• Patients with at least one measurement of sofosbuvir or daclatasvir plasma concentration
• Follow-up of at least 3 months after the end of treatment

Exclusion Criteria:

• Patients with severe renal failure (estimated glomerular filtration rate (eGFR)<30ml/min/1.73m2)
• Patients with liver transplantation during therapy